Navigation Links
Newly Published Data Demonstrates Superiority of Cipralex Over,Duloxetine for Acute Treatment of Depression

he efficacy and tolerability of Cipralex(R) compared to duloxetine and its key findings include(1):

- Patients taking Cipralex(R) demonstrated significantly greater improvement in depression symptoms at week eight (acute treatment) than patients taking duloxetine. This superiority was evident after the first week of treatment and was maintained at all time points until week 16 (p<0.05)(1)

- Cipralex(R) was at least as effective as duloxetine at 24 weeks of treatment, the primary endpoint of the study (p=0.055)(1).

- Patients treated with Cipralex showed significantly better functioning in their work, family and social life at week 8 and week 24, compared to duloxetine(1)

- Cipralex(R) was better tolerated than duloxetine. Significantly more duloxetine patients withdrew from the study due to adverse events than those treated with Cipralex(R) (17 percent versus nine percent respectively)(1)

"Since current guidelines urge the long-term treatment of depression, it is vital that treatments offer the required efficacy coupled with acceptable tolerability," continued Dr Wade. "These new data add to the increasing evidence that Cipralex(R) may have a significant clinical advantage in this respect."

Notes to Editors

About the clinical study

The study was designed to look at the efficacy and tolerability of Cipralex(R) compared to duloxetine in patients with moderate to severe MDD over 24 weeks, with a secondary endpoint at eight weeks (acute treatment). The double-blind, fixed-dose, comparative study included 294 patients with MDD from 35 centres in nine countries. Patients were randomised to either Cipralex(R) (n=143) or duloxetine (n=151), at dosing regimens recommended in the package inserts in participating countries (Cipralex(R) 20mg, duloxetine 60mg)(1).

Efficacy (using the MADRS rating scale as the primary scale) and tolerability were assessed at baseline and after 1, 2, 4, 8, 12, 16, 20 and 24 weeks; a sa
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
2. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
3. Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
4. Newly Published Study Reveals Femara Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women
5. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
6. ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
7. MRI Detects Cancers in the Opposite Breast of Women Newly Diagnosed with Breast Cancer
8. Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia
9. Newly Released Canadian Data Links Vaccines with Pervasive Developmental Disorder
10. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
11. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
Post Your Comments:
(Date:10/7/2008)...ighting CIMZIA,s long-term benefits and value in,m...ed at American College,of Gastroenterology (ACG), ...ta from two studies,presented this week by UCB at ...ual Meeting demonstrate that CIMZIA(R) (certolizum...or Necrosis Factor alpha) - provides,sustained imp...
(Date:10/7/2008)...ght On-Demand Tests for Use on the GeneXpert(R) ...Calif., Oct. 7 /- Cepheid (...(TM) vanA/vanB as a European CE,IVD Mark product u...,Medical Devices. The test delivers rapid detectio...ly associated with vancomycin-resistant,enterococc...
(Date:10/6/2008)... the American College of Gastroenterology Annual ...la., Oct. 6 /- Combined results from ...ege of Gastroenterology Annual,Scientific Meeting ...R,resulted in higher healing rates than lansoprazo...ve esophagitis (EE). TAK-390MR combines,dexlansopr...
(Date:10/6/2008)... feature children, parents discussing clinical ...., Oct. 6 /PRNewswire-USNewswire/ -- From asthma a...dren saves lives and improves their,health and wel...es of,Health (NIH), "Children and Clinical Studies...h.gov ), offers parents and health,care providers ...
Breaking Medicine Technology:CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 2CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 3CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 6CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 7CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 8CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 9Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection 2Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection 3Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection 4Takeda's Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed 2Takeda's Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed 3Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 2Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 3Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 4Variant of Mad Cow Disease May Be Transmitted by Blood Transfusions According to Animal Study 2907 1Variant of Mad Cow Disease May Be Transmitted by Blood Transfusions According to Animal Study 2907 2Variant of Mad Cow Disease May Be Transmitted by Blood Transfusions According to Animal Study 2907 3Arctic ice on the verge of another all time low 4632 1Arctic ice on the verge of another all time low 4632 2Arctic ice on the verge of another all time low 4632 3New beta blocker to offer hope to heart and lung sufferers 4629 1New beta blocker to offer hope to heart and lung sufferers 4629 2SulphCo Adds New Board Member 7376 1SulphCo Adds New Board Member 7376 2
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
...chemical chip to explain the important role a cert...lls. The finding could lead to new cancer drugs wi...ohn Hopkins University, led by Andre Levchenko, ha...they used their patented microfluidic chip to stud...
...ressing olive leaves, may act as an antioxidant to...a study using sunflower oil. // "The outcome of th...n be used in practical operation to extend the fry...rote lead author Radwan Farag from Cairo Universit...
...roved by the UAE Ministry of Health (MOH) against ...ded with a //prequalification status by the World ...vaccine against rotavirus gastroenteritis has rece...ation endorses the Rotarix quality, safety and eff...
...ealth are extremely optimistic about the recent ch...r management //of emergency care and reduce waitin...an has been initiated to effectively manage space ... "bed site manager" is newly designated in the hos...
Other Medicine News:Health News:Biochemical Chip Solves Cell-mating Puzzle 2Health News:Biochemical Chip Solves Cell-mating Puzzle 3Health News:Olive Leaf Juice Could Be Edible Oil Antioxidant 2Health News:WHO Awards Prequalification Status to the First UAE Approved Vaccine 2
...is the latest addition to the HemoCue glucose prod...ystem combines the precision and accuracy of a lab...and ease of use. The new pocket size analyser also... and time for up to 600 measurements. The stored d...
VIDAS tests are presented in individual, ready to use form. Each test is composed of a strip and a SPR. The strip contains all the reagent required for the reaction (buffer, conjugate and substrate.
ELISA for the detection of C. difficile toxin A in stool specimens
Clostridium difficile Toxin A Rapydtest® is a fast, simple and highly sensitive test for the rapid and reliable detection of C. difficile Toxins A in faeces.
Medicine Products: